A series of quinazolin‐4( 3H )‐one‐morpholine hybrids as anti‐lung‐cancer agents: Synthesis, molecular docking, molecular dynamics, ADME prediction and biological activity studies
Chemical Biology & Drug Design · 2024-07 · 104 (1)
DOI: 10.1111/cbdd.14599 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, online erschienen am 22.07.2024. Verfasst von Feyzi Sinan Tokalı und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Material and Material Processing Technologies, Kars Vocational School, Kafkas University, Kars, Turkey. Hauptthemen laut MEDLINE: Molecular Docking Simulation, Molecular Dynamics Simulation, Antineoplastic Agents, Lung Neoplasms. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
In this study, we synthesized 15 novel quinazoline‐morpholinobenzylideneamino hybrid compounds from methyl anthranilate and we assessed their cytotoxicity via in vitro assays against A549 and BEAS‐2B cell lines. Molecular docking studies were conducted to evaluate the protein‐ligand interactions and inhibition mechanisms on nine different molecular targets, while molecular dynamics (MD) simulations were carried out to assess the stability of the best docked ligand–protein complexes. Additionally, ADME prediction was carried out to determine physicochemical parameters and drug likeness. According to the cytotoxicity assays, compound 1 (IC 50 = 2.83 μM) was found to be the most active inhibitor against A549 cells. While the selectivity index (SI) of compound 1 is 29, the SI of the reference drugs paclitaxel and sorafenib, used in this study, are 2.40 and 4.92, respectively. Among the hybrid compounds, 1 has the best docking scores against VEGFR1 (−11.744 kcal/mol), VEGFR2 (−12.407 kcal/mol) and EGFR (−10.359 kcal/mol). During MD simulations, compound 1 consistently exhibited strong hydrogen bond interactions with the active sites of VEGFR1 and 2, and these interactions were maintained for more than 90% of the simulation time. Additionally, the RMSD and RMSF values of the ligand–protein complexes exhibited high stability at their minimum levels around 1–2 Å. In conclusion, these findings suggest that compound 1 may be a potent and selective inhibitor candidate for lung cancer treatment and inhibition of VEGFR2, especially.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Material and Material Processing Technologies, Kars Vocational School, Kafkas University, Kars, Turkey.
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, Istanbul, Turkey.
- Department of Medical Biology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Turkey.
- Department of Biotechnology, Institute of Health Sciences, Bezmialem Vakif University, Istanbul, Turkey.
ORCID-Profile: Feyzi Sinan Tokalı, Halil Şenol, Şeyma Ateşoğlu, Fahri Akbaş
Zitieren
APA
Tokalı, F. S., Şenol, H., Ateşoğlu, Ş., & Akbaş, F. (2024). A series of quinazolin‐4( 3H )‐one‐morpholine hybrids as anti‐lung‐cancer agents: Synthesis, molecular docking, molecular dynamics, ADME prediction and biological activity studies. Chemical Biology & Drug Design, 104(1). https://doi.org/10.1111/cbdd.14599
Vancouver
Tokalı FS, Şenol H, Ateşoğlu Ş, Akbaş F. A series of quinazolin‐4( 3H )‐one‐morpholine hybrids as anti‐lung‐cancer agents: Synthesis, molecular docking, molecular dynamics, ADME prediction and biological activity studies. Chemical Biology & Drug Design. 2024;104(1). doi:10.1111/cbdd.14599
BibTeX
@article{Tokal2024,
author = {Tokalı, Feyzi Sinan and Şenol, Halil and Ateşoğlu, Şeyma and Akbaş, Fahri},
title = {A series of quinazolin‐4( 3H )‐one‐morpholine hybrids as anti‐lung‐cancer agents: Synthesis, molecular docking, molecular dynamics, ADME prediction and biological activity studies},
journal = {Chemical Biology & Drug Design},
year = {2024},
volume = {104},
number = {1},
doi = {10.1111/cbdd.14599}
}
EUVIMED